Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug 27;16(5):828-835.
doi: 10.3390/idr16050064.

Bloodstream Infections Due to Wild-Type Pseudomonas aeruginosa: Carbapenems and Ceftazidime/Avibactam Prescription Rate and Impact on Outcomes

Carlo Pallotto  1 , Andrea Tommasi  1 , Elisabetta Svizzeretto  1 , Giovanni Genga  1 , Giulia Gamboni  1 , Anna Gidari  2 , Daniela Francisci  1
Affiliations

Bloodstream Infections Due to Wild-Type Pseudomonas aeruginosa: Carbapenems and Ceftazidime/Avibactam Prescription Rate and Impact on Outcomes

Carlo Pallotto et al. Infect Dis Rep. .

Abstract

Background: Pseudomonas aeruginosa is one of the major concerns among bacterial diseases even when it shows a wild-type susceptibility pattern. In 2020, EUCAST reconsidered antibiogram interpretation shifting "I" from "intermediate" to "sensible, increased exposure" with possible significant impact on antibiotic prescription. The aim of this study was to evaluate mortality in patients with P. aeruginosa bloodstream infections treated with antipseudomonal penicillins or cephalosporins vs. carbapenems and ceftazidime/avibactam.

Methods: This is a retrospective observational study. All the patients with a bloodstream infection due to P. aeruginosa admitted to our hospital were enrolled. Exclusion criteria were as follows: extremely critical conditions, age <18 years, pregnancy, isolation of a strain non-susceptible to piperacillin/tazobactam and antipseudomonal cephalosporins. Patients were divided into group A (treatment with carbapenems or ceftazidime/tazobactam) and group B (treatment with antipseudomonal penicillin or cephalosporins).

Results: We enrolled 77 patients, 56 and 21 in groups A and B, respectively. The two groups were homogeneous for age, sex, and biochemical and clinical characteristics at admission. All-cause in-hospital mortality was 17/56 (30.4%) and 3/21 (14.3%) in groups A and B, respectively (p > 0.1). In group A, in-hospital BSI-related mortality was 23.2% (13/56), while it was 14.3% (3/21) in group B (p > 0.1). After multivariate analysis, only the PITT score represented a risk factor for BSI-related mortality (OR 2.917, 95% CI 1.381-6.163).

Conclusions: Both all-cause and BSI-related mortality were comparable between the two groups. Treatment with carbapenem or ceftazidime/avibactam did not represent a protective factor for mortality in wild-type P. aeruginosa BSI.

Keywords: BSI; Pseudomonas aeruginosa; antimicrobial stewardship; bloodstream infections; carbapenem sparing.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare.

References

    1. Kanj S.S., Kanafani Z.A. Current concepts in antimicrobial therapy against resistant gram-negative organisms: Extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa. Mayo Clin. Proc. 2011;86:250. doi: 10.4065/mcp.2010.0674. - DOI - PMC - PubMed
    1. World Health Organization . WHO Bacterial Priority Pathogens List, 2024: Bacterial Pathogens of Public Health Importance to Guide Research, Development and Strategies to Prevent and Control Antimicrobial Resistance. World Health Organization; Geneva, Switzerland: 2024.
    1. Derin O., Sahin M., Dumlu R., Basgonul S., Bayrak A.D., Arduc S., Bayram S., Mikaliyova N., Kanturk A., Yildiz Sevgi D., et al. Registry-Based retrospective cohort study of mortality among adults admitted to intensive care units in Istanbul with hospital acquired Pseudomonas aeruginosa bloodstream-infection between 2014–2021. Antibiotics. 2024;13:90. doi: 10.3390/antibiotics13010090. - DOI - PMC - PubMed
    1. Elfadadny A., Ragab R.F., Al Harbi M., Badshah F., Ibanez-Arancibia E., Farag A., Hendawy A.O., De Los Rios-Escalante P.R., Aboubakr M., Zakai S.A., et al. Antimicrobial resistance of Pseudomonas aeruginosa: Navigating clinica impacts, current resistance trends and innovations in breaking therapies. Front. Microbiol. 2024;15:1374466. doi: 10.3389/fmicb.2024.1374466. - DOI - PMC - PubMed
    1. Tuon F.F., Gortz L.W., Rocha J.L. Risk factors for pan-resistant Pseudomonas aeruginosa bacteremia and the adequacy of antibiotic therapy. Braz. J. Infect. Dis. 2012;16:351. doi: 10.1016/j.bjid.2012.06.009. - DOI - PubMed

LinkOut - more resources